Artikel
Microalbuminuria in hypertensives and the body mass index –
Suche in Medline nach
Autoren
Veröffentlicht: | 8. August 2006 |
---|
Gliederung
Text
Background: In a long-term study (mean observation time 42.5 months) with non-diabetic hypertensives microalbuminuria (MAU) could be shown to be an independent risk factor for cardio- and cerebrovascular events. All patients received ramipril as basic antihypertensive treatment.
The correlation between MAU as risk factor and the body mass index (bmi) was investigated in a subgroup analysis.
Methods: 3518 patients (pts) were assigned to groups according to bmi as normal weight (wt), pre-adipose, or adipose (2000 WHO-definition: normal weight: bmi=18.5-24.9, pre-adipose: 25-29.9, adipose: >= 30).
End point rates (combined cardio-,cerebrovascular events and total mortality) were analysed for present or missing microalbuminuria at the start of the observation period.
Results: group distribution: normal wt: n=705 (20.0%), pre-adipose: n=1734 (49.3%), adipose: n=1079 (30.7%). At the start of the observation period, pts who did not have a normal wt showed higher incidence of pathological proteinuria than those with normal wt (38.0% vs. 33.8%).
Overall, 1188 pts showed MAU: normal wt 224 (31.8 %), pre-adipose 587 (33.9%), adipose 377 (34.9%). The event rate without/with MAU was: in the normal wt pts 7.0 / 11.6%, in the pre-adipose group 5.6 /12.6 % and for adipose pts 9.6 / 10.9%.
Independantly of bmi-group all pts had a higher event rate if they did have MAU. Normal wt pts with MAU had a higher event rate than adipose pts without MAU.
Conclusion: In all bmi-groups, the presence of microalbuminuria indicates an increase in cardiovascular risk. The prognosis for normal wt hypertensives with MAU is worse than that for adipose hypertensives without MAU.